Company: SMNR
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001213900-25-044889
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
ITem
1. Unaudited CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DENALI CAPITAL ACQUISITION CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

    March 31,  2025  
    December 31,  2024 

    (Unaudited)  

    Assets 

    Cash on hand 
    $2,736  
    $16,868 
  
    Total current assets 
     2,736  
     16,868 

    Cash and Investments held in trust 
     9,145,167  
     9,021,005 
  
    Total assets 
    $9,147,903  
    $9,037,873 

    Liabilities and Shareholders’ Deficit 

    Accounts Payable and accrued offering costs and expenses 
    $4,772,883  
    $4,640,414 
  
    Accrued interest expense -related party 
     91,764  
     74,555 
  
    Accrued interest expense - others 
     68,351  
     58,586 
  
    Promissory Note - related party 
     1,523,237  
     1,423,237 
  
    Promissory Note - Others 
     1,395,482  
     1,350,292 
  
    Total current liabilities 
     7,851,717  
     7,547,084 

    Deferred underwriter compensation 
     2,887,500  
     2,887,500 
  
    Total liabilities 
     10,739,217  
     10,434,584 

    Commitments and contingencies 

    Class A ordinary shares subject to possible redemption 751,837 shares at redemption value of $12.16 and $12.00 per share as of March 31, 2025 and December 31, 2024, respectively 
     9,145,167  
     9,021,005 

    Shareholders’ Deficit: 

    Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding 
     -  
     - 
  
    Class A ordinary shares, $0.0001 par value; 200,000,